MedTrace Logo

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

NCT05914610 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-08-25

No results posted yet for this study

Summary

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Conditions

Interventions

DRUG

Envolimab

Envolizumab 300mg, D1, ih, Q3W 4-6cycles

DRUG

Fruquintinib

Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

DRUG

Tegafur

Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-07-30
Completion
2028-07-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05914610 on ClinicalTrials.gov